schizandrin b has been researched along with Inflammation in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Han, J; Hua, J; Khan, ZA; Liang, G; Lin, K; Luo, W; Wang, Y; Wu, G; Zhang, Q | 1 |
| Guo, H; Hu, Q; Hu, Z; Li, G; Peng, H; Pi, L; Tang, G; Xiao, Z; Zhang, Z; Zhou, C | 1 |
| Dong, C; He, Z; Liao, W; Liu, J; Song, C; Song, Q; Song, T; Su, X; Xiong, Y; Yang, S; Zhou, J | 1 |
| Liao, X; Pang, Y; Wang, X; Wei, L; Zhang, Y | 1 |
| Guo, S; Lin, Q; Meng, Y; Qin, X; Qin, Z; Shi, M | 1 |
| An, F; Guo, M; Hong, M; Lu, Y; Wei, X | 1 |
| Bao, J; Chen, W; He, Y; Hu, P; Jiang, L; Ma, C; Moqbel, SAA; Ran, J; Wu, L; Xiong, Y; Xu, K; Xu, L | 1 |
| Feng, Z; Li, X; Liang, G; Mou, Z; Qian, J; Xu, Z; Zheng, X; Zhuang, F | 1 |
| Ji, ZR; Xue, WL; Zhang, L | 1 |
| Guo, SE; Huang, Q; Lin, QN; Liu, YD; Qin, X; Zhang, ZM; Zhou, R | 1 |
| Chen, T; Huang, W; Liang, G; Qian, J; Qian, Y; Wang, J; Wang, Z; Wu, G; You, S | 1 |
| Chan, WM; Chen, J; Ko, KM; Leong, PK; Leung, HY; Wong, HS | 1 |
| Araki, R; Hiraki, Y; Inatomi, Y; Nishida, S; Yabe, T | 1 |
| Liu, N; Yang, L; Zhao, JH; Zheng, JX; Zhou, ZK; Zhuang, YS | 1 |
| Chae, HS; Choi, JG; Han, SH; Kang, OH; Keum, JH; Kim, SB; Kim, YS; Kwon, DY; Mun, SH; Oh, YC; Shin, DW | 1 |
| Jung, CH; Lee, DH; Lee, TH | 1 |
16 other study(ies) available for schizandrin b and Inflammation
| Article | Year |
|---|---|
Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88-Dependent Inflammation.
Topics: Animals; Cytokines; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Inflammation; Mice; Myeloid Differentiation Factor 88 | 2022 |
Schisandrin B Alleviates Diabetic Cardiac Autonomic neuropathy Induced by P2X7 Receptor in Superior Cervical Ganglion via NLRP3.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Inflammation; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2X7; Superior Cervical Ganglion | 2023 |
Protective efficacy of Schizandrin B on ameliorating nephrolithiasis via regulating GSK3β/Nrf2 signaling-mediated ferroptosis in vivo and in vitro.
Topics: Animals; Ferroptosis; Glycogen Synthase Kinase 3 beta; Inflammation; Nephrolithiasis; NF-E2-Related Factor 2; Oxalates; Rats; Rats, Sprague-Dawley | 2023 |
Schisandrin B regulates MC3T3-E1 subclone 14 cells proliferation and differentiation through BMP2-SMADs-RUNX2-SP7 signaling axis.
Topics: 3T3 Cells; Animals; Bone Morphogenetic Protein 2; Cell Differentiation; Cell Proliferation; Core Binding Factor Alpha 1 Subunit; Cyclooctanes; Heart; Inflammation; Lignans; Liver; Mice; Osteoblasts; Polycyclic Compounds; Schisandra; Signal Transduction; Smad Proteins; Sp7 Transcription Factor | 2020 |
Schisandrin B inhibits LPS-induced inflammatory response in human umbilical vein endothelial cells by activating Nrf2.
Topics: Anti-Inflammatory Agents; Cyclooctanes; Endothelium, Vascular; Heme Oxygenase-1; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-8; Lignans; Lipopolysaccharides; NF-E2-Related Factor 2; NF-kappa B; Polycyclic Compounds; RNA, Small Interfering; Schisandra; Signal Transduction; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2017 |
Comparative Effects of Schisandrin A, B, and C on Acne-Related Inflammation.
Topics: Acne Vulgaris; Anti-Inflammatory Agents; Cyclooctanes; Humans; Inflammation; Lignans; MAP Kinase Signaling System; Polycyclic Compounds; Propionibacterium acnes; THP-1 Cells | 2017 |
Schisandrin B ameliorated chondrocytes inflammation and osteoarthritis via suppression of NF-κB and MAPK signal pathways.
Topics: Animals; Anti-Inflammatory Agents; Cell Survival; Cells, Cultured; Chondrocytes; Cyclooctanes; Dose-Response Relationship, Drug; Inflammation; Lignans; MAP Kinase Signaling System; Matrix Metalloproteinases; NF-kappa B; Osteoarthritis; Polycyclic Compounds; Rats; Rats, Sprague-Dawley; Schisandra; Structure-Activity Relationship | 2018 |
Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress.
Topics: Animals; Cyclooctanes; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Inflammation; Lignans; Mice; Mice, Inbred C57BL; Molecular Conformation; Oxidative Stress; Polycyclic Compounds; Reactive Oxygen Species; Streptozocin | 2019 |
Schisandrin B Attenuates Inflammation in LPS-Induced Sepsis Through miR-17-5p Downregulating TLR4.
Topics: Animals; Anti-Inflammatory Agents; Cyclooctanes; Down-Regulation; Inflammation; Interleukin-1beta; Lignans; Lipopolysaccharides; Macrophages; Mice; MicroRNAs; Polycyclic Compounds; Sepsis; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2019 |
Schisandrin B ameliorates high-glucose-induced vascular endothelial cells injury by regulating the Noxa/Hsp27/NF-κB signaling pathway.
Topics: Anti-Inflammatory Agents; Cell Survival; Cells, Cultured; Cyclooctanes; Endothelial Cells; Glucose; HSP27 Heat-Shock Proteins; Humans; Inflammation; Lignans; NF-kappa B; Polycyclic Compounds; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2019 |
Schizandrin B attenuates angiotensin II induced endothelial to mesenchymal transition in vascular endothelium by suppressing NF-κB activation.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Cells, Cultured; Cyclooctanes; Cytokines; Disease Models, Animal; Endothelium, Vascular; Fibrosis; Gene Expression Regulation; Inflammation; Lignans; Male; Mice; Mice, Inbred C57BL; NF-kappa B p50 Subunit; Oxidative Stress; Phenotype; Polycyclic Compounds; Signal Transduction; Vascular Remodeling | 2019 |
Differential Action between Schisandrin A and Schisandrin B in Eliciting an Anti-Inflammatory Action: The Depletion of Reduced Glutathione and the Induction of an Antioxidant Response.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Concanavalin A; Cyclooctanes; Cytokines; Edema; Enzyme-Linked Immunosorbent Assay; Female; Glutathione; Glutathione Transferase; Inflammation; Lignans; Lipopolysaccharides; Mice; Mice, Inbred ICR; Polycyclic Compounds; RAW 264.7 Cells | 2016 |
Gomisin N ameliorates lipopolysaccharide-induced depressive-like behaviors by attenuating inflammation in the hypothalamic paraventricular nucleus and central nucleus of the amygdala in mice.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Central Amygdaloid Nucleus; Cyclooctanes; Depression; Dose-Response Relationship, Drug; Inflammation; Inflammation Mediators; Lignans; Lipopolysaccharides; Male; Mice; Paraventricular Hypothalamic Nucleus; Plant Extracts; Polycyclic Compounds; Schisandra | 2016 |
Anti-Inflammatory Effects of Schisandrin B on LPS-Stimulated BV2 Microglia via Activating PPAR-γ.
Topics: Anti-Inflammatory Agents; Cell Line; Cyclooctanes; Enzyme Activation; Humans; Inflammation; Lignans; Lipopolysaccharides; Microglia; Polycyclic Compounds; PPAR gamma | 2017 |
Gomisin N has anti-allergic effect and inhibits inflammatory cytokine expression in mouse bone marrow-derived mast cells.
Topics: Animals; Anti-Allergic Agents; Bone Marrow Cells; Calcimycin; Calcium Ionophores; Carcinogens; Cells, Cultured; Cyclooctanes; Gene Expression Regulation; Hypersensitivity; Inflammation; Inflammation Mediators; Interleukin-6; Lignans; Male; Mast Cells; Mice; Mice, Inbred BALB C; Polycyclic Compounds; Tetradecanoylphorbol Acetate | 2011 |
Neuroprotective effects of Schisandrin B against transient focal cerebral ischemia in Sprague-Dawley rats.
Topics: Animals; Antioxidants; Cerebral Infarction; Cyclooctanes; Drugs, Chinese Herbal; Inflammation; Interleukin-1beta; Ischemic Attack, Transient; Lignans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neuroprotective Agents; Plant Extracts; Polycyclic Compounds; Rats; Rats, Sprague-Dawley; Reperfusion; Schisandra; Tumor Necrosis Factor-alpha | 2012 |